Related references
Note: Only part of the references are listed.Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients
Daniel E. Speiser et al.
JOURNAL OF IMMUNOTHERAPY (2010)
TLR Cross-Talk Specifically Regulates Cytokine Production by B Cells from Chronic Inflammatory Disease Patients
Madhumita Jagannathan et al.
JOURNAL OF IMMUNOLOGY (2009)
A New Nonparametric Approach for Baseline Covariate Adjustment for Two-Group Comparative Studies
Alexander Schacht et al.
BIOMETRICS (2008)
Nanoparticles target distinct dendritic cell populations according to their size
Vania Manolova et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma
Maja A. Hofmann et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials
J. Clark et al.
ALLERGY (2007)
Decreased markers of atopy in children with presumed early exposure to allergens, unhygienic conditions, and infections
Iwona Stelmach et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2007)
Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce
G. W. Canonica et al.
ALLERGY (2007)
Allergen immunotherapy
Matthew A. Rank et al.
MAYO CLINIC PROCEEDINGS (2007)
Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis
Peter S. Creticos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults
Thomas M. Kuendig et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
A Carpentier et al.
NEURO-ONCOLOGY (2006)
Therapeutic potential of Toll-like receptor 9 activation
Arthur M. Krieg
NATURE REVIEWS DRUG DISCOVERY (2006)
Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction
EM Hessel et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine
CL Cooper et al.
VACCINE (2004)
TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells
H Matsushima et al.
JOURNAL OF IMMUNOLOGY (2004)
A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant
SA Halperin et al.
VACCINE (2003)
Long-term efficacy of preseasonal grass pollen immunotherapy in children
PA Eng et al.
ALLERGY (2002)
Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study)
C Möller et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2002)
Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study.
GB Pajno et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2001)
Share Paper
